Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air (NASDAQ: XAIR) has received a 180-day extension from Nasdaq until August 4, 2025, to regain compliance with the minimum bid price requirement. This follows an initial notification on August 8, 2024, when the company first failed to maintain the minimum $1.00 bid price per share requirement. The company's stock will continue trading on the Nasdaq Capital Market under 'XAIR' during this period.
To regain compliance, Beyond Air must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the deadline. Nasdaq may extend this requirement to up to 20 consecutive business days. The company has indicated its intention to cure the deficiency, including the possibility of implementing a reverse share split if necessary.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on nitric oxide (NO) solutions, has announced its upcoming fiscal third quarter 2025 financial results conference call. The company will release its financial results for the period ended December 31, 2024, on Monday, February 10, 2025, after market close.
The conference call will be held at 4:30 PM ET on the same day, with domestic and international dial-in numbers available. A webcast of the conference call will be accessible through the Events section of the company's website, with a replay available online after the call.
Beyond Air (NASDAQ: XAIR) has received market authorization from Australia's Therapeutic Goods Administration (TGA) for its LungFit® PH as a Class IIb medical device. The device generates nitric oxide (NO) from room air for delivery into ventilator breathing circuits at user-set concentrations.
The company plans to initiate shipments to Australia through its Asian Pacific partner, Getz Healthcare, in the coming months. This approval follows the recent CE Mark authorization in the European Union, with additional market approvals expected throughout 2025.
LungFit PH uses patented Ionizer® technology to generate unlimited on-demand NO from ambient air, delivering doses ranging from 0.5 ppm to 80 ppm. The system features a Smart Filter that lasts 12 hours and removes toxic nitrogen dioxide byproducts. Operating with the power equivalent of a 60-watt light bulb, the device eliminates the need for tanks or chemicals, supporting hospital sustainability initiatives by reducing carbon footprint.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, announced that its Chairman and CEO, Steve Lisi, will participate in the Lytham Partners 2025 Investor Healthcare Summit. The event will occur virtually on Monday, January 13, 2025.
Lisi will engage in one-on-one meetings and deliver a presentation scheduled for 10:30 a.m. ET on the same day. The presentation will be webcast live and can be accessed via the conference home page or directly through the provided link. A replay will also be available through the same links. Investors interested in arranging one-on-one meetings can do so by contacting Lytham Partners at 1x1@lythampartners.com.
Beyond Cancer has received approval from the Israeli Ministry of Health to conduct a Phase 1b clinical trial evaluating Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in combination with anti-PD-1 therapy. The trial will enroll up to 20 patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumors who have progressed or shown prolonged stable disease on PD-1 inhibitors.
The study will be conducted at four Israeli sites starting Q1 2025, with topline data expected in H2 2025. The primary objective is to assess preliminary efficacy through objective response rate and duration of response. Preclinical studies showed that a single UNO dose increased PD-L1 expression and improved overall survival compared to anti-PD-1 alone.
Beyond Air (NASDAQ: XAIR) has received European CE mark approval for its LungFit® PH system, a nitric oxide generator for treating newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension. This approval enables marketing in the EU and other regions recognizing CE certification. The approval triggers a $1 million milestone payment from Asia-Pacific partner Getz Healthcare, with whom Beyond Air has a commercialization agreement covering multiple Asian markets. The LungFit PH system generates nitric oxide from ambient air using Ionizer® technology, eliminating the need for tanks or chemicals, and operates with minimal power consumption equivalent to a 60-watt light bulb.
NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has appointed Nobel Laureate Roger D. Kornberg to its Scientific Advisory Board. Kornberg, who won the 2006 Nobel Prize in Chemistry for his work in molecular biology, will help accelerate the development of treatments for Autism Spectrum Disorder (ASD) and other neurological disorders. As a Stanford University professor and expert in eukaryotic gene transcription, Kornberg will provide insights into molecular mechanisms underlying these disorders and assist in identifying novel therapeutic targets.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in Nitric Oxide (NO) treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place from December 3-5, 2024, in New York. Steve Lisi, the company's Chairman and CEO, will engage in one-on-one meetings and lead a fireside chat scheduled for Wednesday, December 4, 2024, at 4:30 pm ET.
Beyond Air (NASDAQ: XAIR) reported fiscal Q2 2025 results with revenues of $0.8 million, up 17% from the previous quarter. The company strengthened its balance sheet through a $20.6 million private placement and restructured its debt, retiring $17.5 million from Avenue Capital while securing an $11.5 million loan agreement. Commercial progress includes a 60% increase in hospital contracts and $3.5 million in annualized contracted revenue as of October 1, 2024. The company's cash position of $28.4 million, combined with expected revenue growth, is projected to provide runway through June 2026.
Beyond Cancer presented promising preclinical data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy at SITC 2024. The study showed that LV UNO combined with anti-rPD-L1 doubled tumor growth inhibition and improved survival in MAT B III tumor-bearing rats compared to anti-rPD-L1 alone. Additionally, LV UNO proved more effective than High Volume UNO in reducing tumor volumes in CT26 BALB/c mice when combined with anti-mPD-1 treatment. The research demonstrated enhanced nitro-tyrosine staining with LV UNO, indicating better tumor distribution of nitric oxide and potential improved safety outcomes.